| Revenue growth | FY26 revenue down 12% YoY; Q4 down 24% YoY. |
|---|---|
| Margins | EBITDA margins expected to improve with operating leverage. |
| Order book | Orders in place for new US entity Stellon. |
| Demand visibility | Good visibility for H1 FY27; customers derisking supply chains. |
| Management confidence | High for FY27; expect recovery from temporary structural headwinds. |
Growth
FY26 revenue fell 12% YoY; Q4 revenue down 24%. EBITDA margin stood at 35%. API revenue degrew 12%.
Outlook
Guidance for FY27 growth slightly above historical 18% levels. Capex focused on debottlenecking (₹20-30cr per annum).
Risks
Geopolitical instability in Middle East, US tender delays, and CDSCO certification delays affecting European supplies.
Last quarter's promises, checked
Delivered
- Expected Q4 to be stronger → Delivered Q4 revenue down 24% (= MISS)
- API growth volume-driven → Delivered volume-driven growth (= BEAT)
- WHO GMP for injectables → Delivered certification received (= BEAT)
Partly delivered
- Stellon US sales start → Delivered sales started but insignificant (= PARTIAL)
Missed
- Historical 18% baseline growth → Delivered 12% revenue decline (= MISS)
- EBITDA margins at 40% (ex-startups) → Delivered 35% overall (= MISS)
- Middle East tender recoupment → Delivered ongoing geopolitical delay (= MISS)
Earnings Call filed with BSE, NSE: CONCORDBIO. Summary written with AI assistance from the document.
Concord Biotech Ltd: key numbers
- Share price
- ₹1,453.60
- Market cap
- ₹15,207 Cr
- Revenue (annual)
- ₹1,055 Cr
- Net profit (annual)
- ₹260.9 Cr
- P/E (TTM)
- 55.2×Sector 50.4×
- Promoter holding
- 44.08%+0.00% QoQ
- FII holding
- 7.53%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Concord Biotech Ltd
All →Concord Biotech Bonus Issue
Concord Biotech's board recommended a 1:1 bonus share issue from free reserves. Shareholders will consider this proposal at an upcoming postal ballot on October 24, 2026.
Concord Biotech Bonus Issue
Concord Biotech approved a 1:1 bonus issue of 10.46 crore equity shares. The board also increased the company's authorized share capital to Rs. 22 Crore.
- Value
- ₹10.46 Cr
Concord Biotech Board Meeting Date
Concord Biotech Ltd announced a board meeting for September 23, 2026, to consider a proposal for the declaration of bonus equity shares.
Concord Biotech Business Update
Concord Biotech disclosed a successful USFDA inspection at its Valthera facility with one minor non-GMP observation. No material impact on operations or existing supplies is expected.
Concord Biotech Earnings Call Transcript: Key Takeaways
Concord reports a strong 26% revenue recovery in Q1FY27, pivoting from a challenging FY26 despite previous procurement delays.
Concord Biotech Investor Presentation: Key Takeaways
Concord Biotech reported strong Q1FY27 consolidated performance with 26% revenue growth and 31% PAT growth, driven by a 46% surge in exports and expanding market share in niche fermentation APIs.